



STAFF REPORT
City of Dripping Springs
PO Box 384
511 Mercer Street
Dripping Springs, TX 78620

Submitted By: Aniz Alani, Deputy City Attorney

Council Meeting Date: October 7, 2025

Agenda Item Wording: **Consultation with City Attorney related to opioid lawsuits.**

Background: The City of Dripping Springs has an opportunity to participate in an additional nationwide opioid litigation settlement involving secondary manufacturers—those entities involved in the manufacture of opioid products not previously covered in earlier settlements, namely: Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus.

The Texas Attorney General's Office, in conjunction with the Texas Opioid Abatement Fund Council (TOAFC), has coordinated this latest round of settlement efforts. The settlement participation opportunity follows previous successful engagements with opioid distributors and retailers such as CVS, Walgreens, Walmart, Allergan, Kroger, and Purdue Pharma.

The City has previously approved participation in opioid settlements via:

- Resolution No. 2021-R40 (Texas Term Sheet)
- Resolution No. 2023-R13 (CVS, Walgreens, Walmart, and Allergan)
- Resolution No. 2024-R28 (Kroger)
- Resolution No. 2025-R31 (Purdue Pharma/Sackler)

This new round involves Secondary Manufacturers, as detailed in the National Opioid Settlement documentation received from the settlement administrator, and requires submission of signed participation forms by the designated deadline.

Recommended Council Actions: Authorize participation in secondary opioid manufacturer settlements and authorize execution and submission of participation forms to the settlement administrator.

Attachments: Draft Resolution

Secondary Manufacturer Subdivision Participation and Release Form

Confidential Memo dated March 3, 2023 from Marianne Banks and Marc Calderaro, Bojorquez Law Firm